March 4, 2020 / 1:35 PM / a month ago

BRIEF-DelMar Pharmaceuticals Reports Over 50% Enrollment In Phase 2 Clinical Trial Of VAL-083 For Adjuvant Treatment Of Brain Tumors

March 4 (Reuters) - DelMar Pharmaceuticals Inc:

* DELMAR PHARMACEUTICALS [NASDAQ:DMPI] REPORTS OVER 50% ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF VAL-083 FOR ADJUVANT TREATMENT OF BRAIN TUMORS

* DELMAR PHARMACEUTICALS INC - CONTINUE TO ANTICIPATE AN INITIAL DATA READOUT FOR PHASE 2 STUDY OF VAL-083 BEFORE END OF AUGUST 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below